| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013680268 |
| P356 | DOI | 10.1038/17401 |
| P698 | PubMed publication ID | 10028970 |
| P2093 | author name string | Morimoto K | |
| Morimoto T | |||
| Asano T | |||
| Suthanthiran M | |||
| Shimbo T | |||
| Hojo M | |||
| Lagman M | |||
| Maluccio M | |||
| P2860 | cites work | The transforming growth factor-beta family | Q29615948 |
| Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential | Q33825657 | ||
| Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation | Q36361148 | ||
| Cytokine-induced pseudopodial protrusion is coupled to tumour cell migration | Q36420330 | ||
| Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1 | Q36531643 | ||
| A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance | Q37699443 | ||
| Cyclosporine | Q38733507 | ||
| Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporines antiproliferative effects. | Q41311383 | ||
| Effects of transforming growth factor-beta 1 on human pulmonary adenocarcinoma cell adhesion, motility, and invasion in vitro | Q41631767 | ||
| Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation | Q42245869 | ||
| Cyclosporine stimulates hepatocyte proliferation and accelerates development of hepatocellular carcinomas in rats | Q42506551 | ||
| Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction | Q42768300 | ||
| Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture | Q42801657 | ||
| A murine renal cell carcinoma | Q43649460 | ||
| TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice | Q45345227 | ||
| Risk of neoplasia in renal transplant patients. | Q52870351 | ||
| Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. | Q53436869 | ||
| Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. | Q53596870 | ||
| Cancers following cyclosporine therapy | Q69707718 | ||
| Effects of cyclosporin A on progressive and regressive tumors induced by two cancer lines derived from a single colon carcinoma chemically induced in the rat | Q69738178 | ||
| Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer | Q71601446 | ||
| Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour | Q71976275 | ||
| Renal transplantation | Q72442105 | ||
| Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma | Q73330030 | ||
| P433 | issue | 6719 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cyclosporine | Q367700 |
| P304 | page(s) | 530-534 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Cyclosporine induces cancer progression by a cell-autonomous mechanism. | |
| P478 | volume | 397 |
| Q90512312 | "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation" |
| Q42423816 | A Patient with Refractory Psoriasis Who Developed Sebaceous Carcinoma on the Neck during Cyclosporine Therapy and Showed Rapid Progression |
| Q47684843 | A Rare Combination of Dermatomyositis, Interstitial Pneumonia, and Lung Cancer in a Patient Treated with Immunosuppressive Therapy and Chemotherapy: A Case Report |
| Q48586590 | A cell-permeable NFAT inhibitor peptide prevents pressure-overload cardiac hypertrophy |
| Q57150985 | A child with unresectable biliary rhabdomyosarcoma: 48-month disease-free survival after liver transplantation |
| Q38041260 | A drug safety evaluation of everolimus in kidney transplantation |
| Q44760624 | A new cell-permeable peptide allows successful allogeneic islet transplantation in mice |
| Q40845773 | A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection |
| Q44100057 | A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine |
| Q33575450 | A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma |
| Q42514247 | A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population |
| Q59064527 | A transformed view of cyclosporine |
| Q92322227 | Actualités sur la prise en charge des kératoses actiniques chez les patients transplantés d’organes: Management of actinic keratoses in organ transplant recipients: an update |
| Q34566700 | Advances in myasthenia gravis |
| Q33811481 | Advances in psoriasis therapy |
| Q37784378 | Aggressive Behavior of Nonmelanotic Skin Cancers in Solid Organ Transplant Recipients |
| Q34055699 | Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development |
| Q34775401 | Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy |
| Q43553173 | Angiotensin II receptor blockade: a novel strategy to prevent immunosuppressant-associated cancer progression |
| Q21562115 | Antamanide, a derivative of Amanita phalloides, is a novel inhibitor of the mitochondrial permeability transition pore |
| Q46393235 | Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation |
| Q38156840 | Antineoplastic effects of mammalian target of rapamycine inhibitors |
| Q90446358 | Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients |
| Q40022074 | Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma |
| Q56335977 | Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors |
| Q33986181 | Assessment of immunosuppressant drug carcinogenicity: standard and alternative animal models |
| Q36878427 | Astrocytes--friends or foes in multiple sclerosis? |
| Q36674035 | Autocrine Transforming Growth Factor-beta Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein |
| Q46564996 | Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome |
| Q54042751 | Bcl-2 inhibits calcineurin-mediated Fas ligand expression in antitumor drug-treated baby hamster kidney cells. |
| Q35893172 | Biologics in combination with nonbiologics: efficacy and safety |
| Q34380043 | Bridging the divide: spinal cord repair by cellular transplantation--from research laboratory to therapeutic application. |
| Q74609075 | Bronchogenic carcinoma complicating lung transplantation |
| Q36338871 | Bronchogenic carcinoma in solid organ transplant recipients |
| Q40812380 | CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model |
| Q34357718 | CXCL12/CXCR4 axis triggers the activation of EGF receptor and ERK signaling pathway in CsA-induced proliferation of human trophoblast cells |
| Q37118161 | Ca2+ signaling, genes and the cell cycle |
| Q34581528 | Calcineurin and hypertrophic heart disease: novel insights and remaining questions |
| Q34009025 | Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40 |
| Q39776480 | Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells |
| Q34236648 | Calcineurin inhibitors and the generalization of the presenting protein strategy |
| Q36985818 | Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. |
| Q37220939 | Calcineurin regulates cyclin D1 accumulation in growth-stimulated fibroblasts |
| Q44283210 | Calcineurin-mediated pathway involved in the differentiated phenotype of smooth muscle cells |
| Q37811513 | Can Immunosuppressive Strategies Be Used to Reduce Cancer Risk in Renal Transplant Patients? |
| Q87796374 | Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do |
| Q59360475 | Cancer in kidney transplant recipients |
| Q54447237 | Cancer in transplant recipients. |
| Q33495757 | Cancer incidence in kidney transplant recipients: a study protocol |
| Q38226535 | Cancer risk of immunosuppressants in manufacturing |
| Q37218133 | Cancers after renal transplantation |
| Q35060402 | Carcinosarcoma of native renal pelvis in recipient after a renal transplant: a case report |
| Q35711246 | Cardiac transplant experience with cyclosporine |
| Q37973018 | Case report: Bone tumor of the scapula in a patient undergoing liver transplantation |
| Q59416946 | Causes of mortality after liver transplantation: period of main incidence |
| Q36646357 | Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase |
| Q28591382 | Characterization of a gene encoding two isoforms of a mitochondrial protein up-regulated by cyclosporin A in activated T cells |
| Q34161342 | Chemoprevention of photocarcinogenesis by selected dietary botanicals |
| Q34554736 | Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer |
| Q36023899 | Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients |
| Q38985999 | Clinical features and course of Kaposi's sarcoma in Egyptian kidney transplant recipients |
| Q37811514 | Clinical insights for cancer outcomes in renal transplant patients |
| Q37771531 | Clinical recommendations for the use of everolimus in heart transplantation |
| Q39290636 | Clinical yield of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration for incidental pancreatic cysts in kidney transplant evaluation. |
| Q46946071 | Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. |
| Q40098558 | Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling |
| Q83966238 | Combination therapy with acitretin for psoriasis |
| Q46706318 | Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African–American renal transplant patients |
| Q46387294 | Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes |
| Q56366608 | Complications of Cardiac Transplantation |
| Q38687757 | Comprehensive Review on Colorectal Cancer and Transplant |
| Q90431091 | Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis |
| Q38190678 | Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? |
| Q33371289 | Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience |
| Q37795414 | Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia |
| Q36798362 | Current concepts and perspectives of immunosuppression in organ transplantation |
| Q36204198 | Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation |
| Q36764024 | Current perspectives on FTY720. |
| Q35190088 | Current systemic therapies for psoriasis: where are we now? |
| Q37277787 | Cyclosporin A enhances the ability of trophoblasts to displace the activated human umbilical vein endothelial cell monolayers |
| Q33943659 | Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition. |
| Q37228796 | Cyclosporin A promotes proliferating cell nuclear antigen expression and migration of human cytotrophoblast cells via the mitgen-activated protein kinase-3/1-mediated nuclear factor-κB signaling pathways |
| Q34518356 | Cyclosporin A promotes tumor angiogenesis in a calcineurin-independent manner by increasing mitochondrial reactive oxygen species |
| Q33333473 | Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies |
| Q44149038 | Cyclosporin A therapy differently affects immunological-relevant gene expression following immunization |
| Q39591754 | Cyclosporin A, but not everolimus, inhibits DNA repair mediated by calcineurin: implications for tumorigenesis under immunosuppression |
| Q37247310 | Cyclosporin-A associated malignancy. |
| Q53180942 | Cyclosporine A Inhibits the T-bet-Dependent Antitumor Response of CD8(+) T Cells. |
| Q37277272 | Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. |
| Q33582900 | Cyclosporine A improves adhesion and invasion of mouse preimplantation embryos via upregulating integrin β3 and matrix metalloproteinase-9 |
| Q40395759 | Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells |
| Q39786532 | Cyclosporine A suppresses keratinocyte cell death through MPTP inhibition in a model for skin cancer in organ transplant recipients. |
| Q35085117 | Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. |
| Q35032846 | Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFβ signaling pathway |
| Q42525696 | Cyclosporine inhibits growth through the activating transcription factor/cAMP-responsive element-binding protein binding site in the cyclin D1 promoter |
| Q33399015 | DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance? |
| Q88649024 | De Novo Urologic Malignancies in Renal Transplant Recipients |
| Q35935032 | De novo cancer occurrence after renal transplantation: a medical center experience in Taiwan |
| Q34426430 | De novo malignancies after liver transplantation: a major cause of late death |
| Q43828644 | De novo noncutaneous malignancies in heart transplantation: a single-centre 15-year experience and risk factor analysis |
| Q33622320 | De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppression |
| Q28592115 | Defective T cell development and function in calcineurin A beta -deficient mice |
| Q47614127 | Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at l-selectin and alpha4-integrin prior to infusion |
| Q42153262 | Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis |
| Q39673279 | Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors |
| Q43072401 | Design, synthesis, and immunosuppressive activity of new deoxybenzoin derivatives |
| Q53287574 | Diagnostic role of colour Doppler US at 1-year follow-up after orthotopic liver transplantation. |
| Q53356707 | Dietary grape-seed proanthocyanidin inhibition of ultraviolet B-induced immune suppression is associated with induction of IL-12. |
| Q37699257 | Disappearance of Oral Lichen Planus After Liver Transplantation for Primary Biliary Cirrhosis and Immunosuppressive Therapy in a 63-year-Old Japanese Woman |
| Q64111733 | Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of de novo Malignancies in Solid Organ Transplant Patients |
| Q77966107 | Does cyclosporin A cause cancer? |
| Q38328785 | Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? |
| Q37620385 | Down's syndrome: protection against cancer and the therapeutic potential of DSCR1. |
| Q24795040 | Downregulation of calcineurin activity in cervical carcinoma |
| Q35868949 | Downregulation of telomerase maintenance-related ACD expression in patients undergoing immunosuppresive therapy following kidney transplantation |
| Q93136713 | Effect of Converting From Calcineurin Inhibitor- to Sirolimus-Based Immunosuppressant Regimen on Breast Fibroadenoma Among Kidney Transplant Patients |
| Q40671568 | Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia |
| Q92353153 | Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche |
| Q73901951 | Effect of immunosuppressive therapy on DNA repair and cancer incidence in renal transplant recipients |
| Q35973628 | Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression |
| Q54561722 | Effects of different immunosuppressive regimens on regulatory T-cells in noninflamed colon of liver transplant recipients. |
| Q55265769 | Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. |
| Q54558691 | Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. |
| Q36357244 | Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma |
| Q33614767 | Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients |
| Q38091213 | Emerging roles of store-operated Ca²⁺ entry through STIM and ORAI proteins in immunity, hemostasis and cancer |
| Q42516595 | Epidemiology of keratinocyte carcinomas after organ transplantation |
| Q53692877 | Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells. |
| Q45723362 | Epstein-Barr virus-negative gastric large B-cell lymphoma after kidney transplantation |
| Q39180810 | Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update |
| Q59356682 | Etiology of increased cancer incidence after solid organ transplantation |
| Q28067598 | Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update |
| Q40706040 | Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q34579257 | Extragonadal seminoma after renal transplantation and immunosuppression; treatment in the presence of renal dysfunction: a case report and literature review |
| Q44316561 | Failure of cyclosporin A to induce transforming growth factor beta (TGF-beta) synthesis in activated peripheral blood lymphocytes |
| Q34996895 | Fibrogenesis in chronic allograft rejection: underlying mechanisms and pharmacological control |
| Q43299406 | Fighting malignancy in organ transplant recipients |
| Q42460507 | First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients |
| Q35698913 | From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma |
| Q34071336 | Future prospects for anti-cytokine treatment |
| Q90705248 | Gastric Stump Cancer Following Gastrectomy After Renal Transplantation: A Case Report |
| Q50150011 | Gastrointestinal complications in lung transplant survivors that require surgical intervention |
| Q43224156 | Gene profiling of cyclosporin-enhanced transitional cell carcinoma in rat model |
| Q28139459 | Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT |
| Q44984011 | Glioblastoma in kidney transplant recipients. Report of five cases |
| Q24656612 | Grape seed proanthocyanidines and skin cancer prevention: inhibition of oxidative stress and protection of immune system |
| Q36167226 | Hepatic angiosarcoma and liver transplantation: case report and literature review |
| Q89379957 | Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? |
| Q36956771 | High frequency of bronchogenic carcinoma after single-lung transplantation |
| Q47279577 | High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation |
| Q36353207 | Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity |
| Q57107782 | Hodgkin's disease and B cell lymphoproliferation in rheumatoid arthritis patients treated with methotrexate: a kinetic study of lymph node changes |
| Q33919087 | Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth |
| Q61698619 | Human papillomavirus 16 in a heart transplant recipient |
| Q35943114 | Iatrogenic skin cancer: induction by psoralen/ultraviolet A and immunosuppression of organ transplant recipients |
| Q73435413 | Identification of human TGF-beta1 signal (leader) sequence polymorphisms by PCR-RFLP |
| Q36101742 | Immune disorders and susceptibility to neoplasms |
| Q35050810 | Immune profiling and cancer post transplantation |
| Q37748469 | Immunologic mechanisms in RCC and allogeneic renal transplant rejection. |
| Q38044761 | Immunomodulating options for liver transplant patients |
| Q33709280 | Immunopharmacology: anti-inflammatory therapy targeting transcription factors |
| Q37867072 | Immunosuppression and hepatocellular carcinoma |
| Q37028215 | Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin |
| Q39757990 | Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients |
| Q33880261 | Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort |
| Q79790340 | Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants |
| Q33799731 | Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis |
| Q33908046 | Immunosuppressive drugs: the first 50 years and a glance forward |
| Q36830121 | Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review |
| Q37591675 | Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma |
| Q39402703 | Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice |
| Q34554733 | Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study |
| Q33905617 | Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation |
| Q33929706 | Impaired prostate tumorigenesis in Egr1-deficient mice |
| Q31116926 | In vitro selection of specific RNA inhibitors of NFATc |
| Q37126758 | Incidence and management of colorectal cancer in liver transplant recipients |
| Q27025406 | Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis |
| Q26748580 | Incidence, risk factors and outcomes of de novo malignancies post liver transplantation |
| Q57479210 | Incidence, risk factors and outcomes of malignancies after kidney transplantation in Singapore: a 12-year experience |
| Q84409881 | Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation |
| Q34422854 | Increased incidence of head and neck cancer in liver transplant recipients: a meta-analysis. |
| Q45283332 | Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy |
| Q45862088 | Induction of T cell tolerance to a protein expressed in the cytoplasm through retroviral‐mediated gene transfer |
| Q32065045 | Induction of cell proliferation by cyclosporine A in primary cultures of rat hepatocytes. |
| Q92228497 | Infections after kidney transplantation. Does age matter? |
| Q37416913 | Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. |
| Q51762445 | Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients. |
| Q39021344 | Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma. |
| Q40833406 | Invasion and metastasis of a mammary tumor involves TGF-beta signaling |
| Q79764829 | Investigation of soluble HER2 and transforming growth factor Beta-1 serum levels in gestational trophoblastic disease |
| Q40725068 | Involvement of cell-cell interactions in the rapid stimulation of Cas tyrosine phosphorylation and Src kinase activity by transforming growth factor-beta 1. |
| Q43640092 | Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen |
| Q24791742 | Is telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer? |
| Q43726074 | Isofenphos induced metabolic changes in K562 myeloid blast cells |
| Q34334857 | It takes a tissue to make a tumor: epigenetics, cancer and the microenvironment |
| Q37345079 | Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin |
| Q51354409 | Klotho mitigates cyclosporine A (CsA)-induced epithelial-mesenchymal transition (EMT) and renal fibrosis in rats. |
| Q42493759 | Labial adenocarcinoma after treatment with cyclosporin a in a patient with panuveitis. |
| Q42661308 | Lessons learned about the therapeutic potential of the natural human immune response to lung cancer |
| Q38078347 | Liver Transplantation for HCC: A Review |
| Q57066918 | Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong |
| Q63367353 | Liver Transplantation for Hepatocellular Carcinoma |
| Q35093659 | Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients |
| Q39739700 | Liver transplantation for hepatocellular carcinoma: an update. |
| Q39067623 | Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches |
| Q42260052 | Liver transplantation in lymphoma patients with hepatitis B virus reactivation |
| Q36889006 | Liver versus cardiothoracic transplant candidates and their pretransplant psychosocial and behavioral risk profiles: good neighbors or complete strangers? |
| Q79080644 | Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma |
| Q36141152 | Long-term immunosuppression for prevention of nonviral disease recurrence |
| Q84784742 | Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies |
| Q33346685 | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence |
| Q73366506 | Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma |
| Q36158960 | Lymphomatoid papulosis in a patient with atopic eczema on long-term ciclosporin therapy |
| Q46356692 | Maintenance immunosuppressive therapy in adult renal transplantation: a single center analysis. |
| Q45735035 | Malignancies after heart transplantation: presence of Epstein-Barr virus and cytomegalovirus |
| Q55691329 | Malignancies after lung transplantation. |
| Q35885193 | Malignancies in organ transplant recipients |
| Q94476138 | Malignancy after lung transplantation |
| Q37782262 | Malignancy after renal transplantation: the role of immunosuppression |
| Q84757344 | Malignancy development in lung transplant patients |
| Q37149427 | Malignancy in kidney transplant recipients |
| Q77370274 | Malignant neoplastic disorders following long-term immunosuppression after orthotopic heart transplantation |
| Q38533271 | Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? |
| Q95273672 | Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? |
| Q38221424 | Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. |
| Q36088854 | Management and prevention of post-transplant malignancies in kidney transplant recipients |
| Q38010633 | Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients |
| Q37845384 | Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update. |
| Q35818336 | Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review |
| Q33906170 | Manipulating immune responses with immunosuppressive agents that target NFAT. |
| Q33908049 | Mechanisms of action of cyclosporine. |
| Q27320787 | Melanoma Risk and Survival among Organ Transplant Recipients. |
| Q38070693 | Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma |
| Q34563397 | Metabolic profiling of cell growth and death in cancer: applications in drug discovery |
| Q74170683 | Metastatic extragonadal seminoma associated with cardiac transplantation |
| Q37782499 | Metastatic transitional cell carcinoma of the bladder arising in a patient with bladder autoaugmentation |
| Q34563173 | Methods of in vitro toxicology |
| Q37795526 | Minimization of immunosuppression in adult liver transplantation: new strategies and tools |
| Q44770110 | Minimizing the risk of posttransplant malignancy |
| Q28362221 | Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion |
| Q37269923 | Mitochondrial DNA depletion causes decreased ROS production and resistance to apoptosis |
| Q44208147 | Mitochondrial stress-induced calcium signaling, phenotypic changes and invasive behavior in human lung carcinoma A549 cells |
| Q79739439 | Mixed response after allogeneic haemopoietic-cell transplantation for metastatic renal-cell carcinoma |
| Q53222346 | Molecular events associated with ciclosporin A-induced gingival overgrowth are attenuated by Smad7 overexpression in fibroblasts. |
| Q38107276 | Molecularly targeted therapies for nonmelanoma skin cancers |
| Q60046002 | Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm |
| Q91973746 | Myth: Liver Transplant Provides a Cure for Liver Disease |
| Q58796653 | NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway |
| Q42497668 | Neoplasm incidence in simultaneous pancreas and kidney transplantation: a single-center analysis |
| Q26798306 | Neoplastic disease after liver transplantation: Focus on de novo neoplasms |
| Q73630434 | Neutrophil adhesion to vascular prosthetic surfaces triggers nonapoptotic cell death |
| Q38035612 | New concepts and best practices for management of pre- and post-transplantation cancer. |
| Q33826198 | New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide |
| Q36830358 | Nuclear antigens and auto/alloantibody responses: friend or foe in transplant immunology. |
| Q38228585 | Optimal management of skin cancer in immunosuppressed patients |
| Q89953483 | Optimization of immunosuppressive medication upon liver transplantation against HCC recurrence |
| Q40106532 | Oral bexarotene for post-transplant cutaneous T-cell lymphoma. |
| Q37093943 | Oral lichen planus: controversies surrounding malignant transformation |
| Q42494555 | Oral prednisone use and risk of keratinocyte carcinoma in non-transplant population. The VATTC trial |
| Q35608774 | Organ donors with malignant gliomas: an update |
| Q39960762 | Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer |
| Q42555714 | Overview of immunosuppression in liver transplantation |
| Q34264161 | Overview of side effects of immunosuppressive therapy |
| Q30426882 | Partial nephrectomy in a patient with a left ventricular assist device |
| Q43701719 | Patient perception of skin-cancer prevention and risk after liver transplantation |
| Q24537383 | Phosphorylation of NFATc4 by p38 mitogen-activated protein kinases |
| Q38266892 | Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs |
| Q37965984 | Photodynamic therapy for actinic keratosis in organ transplant patients. |
| Q38611709 | Post-transplantation malignancies: here today, gone tomorrow? |
| Q37348173 | Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. |
| Q54694990 | Posttransplant Kaposi's sarcoma: report from a single center. |
| Q21261410 | Posttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case report |
| Q38086869 | Potential of targeting TGF-β for organ transplant patients |
| Q36103149 | Practical retinoid chemoprophylaxis in solid organ transplant recipients |
| Q36130967 | Preserving the B-cell compartment favors operational tolerance in human renal transplantation |
| Q64999313 | Prevalence of advanced colorectal neoplasm is higher in liver transplant recipients. |
| Q34272004 | Prevention of non-melanoma skin cancer |
| Q91793791 | Primary Cutaneous CD30+ Anaplastic Large T Cell Lymphoma in a Patient Treated with Cyclosporine for Actinic Reticuloid |
| Q34984571 | Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway |
| Q37876951 | Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions |
| Q37035703 | Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy |
| Q38502092 | Prolonged survival of islet allografts in mice treated with rosmarinic acid and anti-CD154 antibody. |
| Q39198216 | Prostate cancer in renal transplant recipients |
| Q46746836 | Prostate cancer in renal transplant recipients |
| Q47943691 | Prostate cancer treatment in renal transplant recipients: a systematic review |
| Q39415022 | Proteome analysis and morphological studies reveal multiple effects of the immunosuppressive drug mycophenolic acid specifically resulting from guanylic nucleotide depletion |
| Q34547719 | Psychosocial and behavioral selection criteria for solid organ transplantation |
| Q41877996 | RCAN-11R peptide provides immunosuppression for fully mismatched islet allografts in mice. |
| Q37387399 | Radiation carcinogenesis in context: how do irradiated tissues become tumors? |
| Q42503484 | Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer |
| Q46755906 | Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis |
| Q43873032 | Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor |
| Q38174585 | Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation |
| Q37952030 | Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report |
| Q42795506 | Recurrent Non-melanoma Skin Cancer: Remission of Field Cancerization after Conversion from Calcineurin Inhibitor- to Proliferation Signal Inhibitor-based Immunosuppression in a Cardiac Transplant Recipient |
| Q73111971 | Reduced levels of Hsp70 result in a therapeutic effect of 15-deoxyspergualin on acute graft-versus-host disease in (DA x LEW)F1 rats |
| Q24534698 | Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A |
| Q73103519 | Regulation of tumor necrosis factor cytotoxicity by calcineurin |
| Q74477425 | Relationship between the activation of heat shock factor and the suppression of nuclear factor-kappaB activity in rat hepatocyte cultures treated with cyclosporine A |
| Q41686009 | Renal transplant in a child with bilateral Wilms' tumor national premiere |
| Q36000874 | Renal transplantation, immunosuppression and the skin: an update |
| Q44491088 | Report of a renal transplanted patient with fibroadenoma occurring in a short time |
| Q49095345 | Requirement of miR-144 in CsA induced proliferation and invasion of human trophoblast cells by targeting titin |
| Q35149292 | Reversal of tumor-induced immunosuppression by TGF-beta inhibitors |
| Q42182238 | Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity |
| Q40182395 | Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model |
| Q64110911 | Risk Factors for Developing Nonmelanoma Skin Cancer after Lung Transplantation |
| Q55266341 | Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network. |
| Q90737442 | Risk of lip cancer after solid organ transplantation in the United States |
| Q40665110 | Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging |
| Q35170428 | Role of tissue stroma in cancer cell invasion |
| Q35403714 | Roles of the immune system in skin cancer. |
| Q36436538 | Rosmarinic Acid Attenuates Cell Damage against UVB Radiation-Induced Oxidative Stress via Enhancing Antioxidant Effects in Human HaCaT Cells |
| Q73327119 | Selection of metastatic tumour phenotypes by host immune systems |
| Q36369190 | Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2 |
| Q36381360 | Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. |
| Q36847294 | Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma |
| Q40446087 | Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth |
| Q39918641 | Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma |
| Q37021743 | Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. |
| Q46187843 | Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria |
| Q46372278 | Sirolimus: a potential chemopreventive agent |
| Q39337780 | Skin Cancers in Organ Transplant Recipients. |
| Q37432717 | Skin cancer after transplantation |
| Q73372447 | Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens |
| Q38210273 | Skin cancer in kidney transplant recipients. |
| Q26851436 | Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? |
| Q37053236 | Skin cancer in transplant recipients, out of the woods. Scientific retreat of the ITSCC and SCOPE. |
| Q51745077 | Skin cancer incidence in renal transplant recipients - a single center study |
| Q42501633 | Skin diseases following organ transplantation--risk factors and new therapeutic approaches |
| Q42493820 | Skin lesions in adult liver transplant recipients: a study of 100 consecutive patients |
| Q24655517 | Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms |
| Q54687840 | Solid tumors following kidney transplantation in children. |
| Q26772295 | Solid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression management |
| Q36161974 | Squamous cell carcinoma of the oral cavity associated with graft versus host disease: report of a case and review of the literature. |
| Q43758879 | Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study |
| Q34243189 | Structure-based optimization of a peptidyl inhibitor against calcineurin-nuclear factor of activated T cell (NFAT) interaction |
| Q43950447 | Superoxide limits cyclosporine-A-induced formation of peroxynitrite in endothelial cells(2). |
| Q34414642 | Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis |
| Q90961227 | Survival after a cancer diagnosis among solid organ transplant recipients in the United States |
| Q44360698 | Swinging the vote for rapamycin |
| Q89641877 | Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients |
| Q42414457 | Systemic methotrexate for prurigo nodularis and keratoacanthomas in actinically damaged skin |
| Q43617024 | T-Cell type acute lymphoblastic leukemia following cyclosporin A therapy for aplastic anemia |
| Q34691800 | TGF-beta antagonists: why suppress a tumor suppressor? |
| Q40247364 | TGF-beta inhibition of CTL re-stimulation requires accessory cells and induces peroxisome-proliferator-activated receptor-gamma (PPAR-gamma). |
| Q34421804 | TGF-beta signaling in cancer--a double-edged sword |
| Q29615427 | TGF-beta signaling in tumor suppression and cancer progression |
| Q51273202 | Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. |
| Q39475329 | Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. |
| Q37132788 | Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives |
| Q26830194 | Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends |
| Q42517229 | The Effect of Conversion from a Calcineurin Inhibitor to Sirolimus on Skin Cancer Reduction in Post-renal Transplantation Patients |
| Q34275895 | The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis |
| Q93000405 | The Role of Calmodulin in Tumor Cell Migration, Invasiveness, and Metastasis |
| Q64253571 | The Role of the Immune System in Cutaneous Squamous Cell Carcinoma |
| Q37614753 | The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. |
| Q34170288 | The current status of liver transplantation for primary hepatic malignancy. |
| Q46187419 | The impact of mTOR inhibitors on the development of malignancy |
| Q42507636 | The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation |
| Q38190674 | The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy |
| Q43673811 | The influence of transforming growth factor-beta1 gene polymorphisms on the severity of gingival overgrowth associated with concomitant use of cyclosporin A and a calcium channel blocker |
| Q24532213 | The latent transforming growth factor beta binding protein (LTBP) family |
| Q37112443 | The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways |
| Q35056031 | The not-so innocent bystander: the microenvironment as a therapeutic target in cancer |
| Q46142658 | The prevalence of malignant neoplasia in feline renal-transplant recipients |
| Q33877893 | The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. |
| Q36103139 | The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients |
| Q35969342 | The role of TGF-beta in epithelial malignancy and its relevance to the pathogenesis of oral cancer (part II). |
| Q33781412 | The role of transforming growth factor-beta in transplant rejection |
| Q38578386 | The safety of calcineurin inhibitors for kidney-transplant patients |
| Q43508145 | Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux |
| Q35680649 | Therapeutic potential of macrolide immunosuppressants in dermatology |
| Q81865902 | Therapy and prognosis of tumors of the genitourinary tract after kidney transplantation |
| Q36410255 | To transplant or not? The importance of psychosocial and behavioural factors before lung transplantation |
| Q34264187 | Topical immunomodulatory agents and their targets in inflammatory skin diseases |
| Q40407750 | Toward the definition of immunosuppressive regimens with antitumor activity. |
| Q43832381 | Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation |
| Q24793319 | Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta |
| Q44735065 | Transitional cell carcinoma in renal transplant recipients: a single center experience |
| Q36916059 | Transitional cell carcinoma of the kidney graft: an extremely uncommon presentation of tumor in renal transplant recipients. |
| Q42845480 | Transplantation: can sirolimus prevent skin cancer in transplant recipients? |
| Q52926198 | Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. |
| Q37610271 | Treatment of myasthenia gravis: current practice and future directions |
| Q44547715 | Tumor and transplantation |
| Q36400864 | Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients |
| Q44963400 | Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies |
| Q34379063 | Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives |
| Q41481044 | Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients. |
| Q36750090 | Use of sirolimus in solid organ transplantation |
| Q34633674 | Vascular profile characterization of liver tumors by magnetic resonance imaging using hemodynamic response imaging in mice |
| Q53301944 | [Immunosuppressive therapy after transplantation. Dermatologic relevance and pathomechanisms]. |
Search more.